{"disease":{"id":"esophagogastric-junction-cancer","name":"esophagogastric junction cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04821778","title":"Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04675138","title":"Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false},{"nct_id":"NCT06277908","title":"Postoperative Morbidity and Mortality After Gastric Cancer Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"P. Herzen Moscow Oncology Research Institute","has_results":false},{"nct_id":"NCT03139487","title":"A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":176,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT04044859","title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"USWM CT, LLC","has_results":false},{"nct_id":"NCT03211377","title":"Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Anyang Tumor Hospital","has_results":false},{"nct_id":"NCT05259696","title":"Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Palleon Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03734913","title":"A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":65,"lead_sponsor_name":"Guangdong Zhongsheng Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06766305","title":"QL1706 Combined With SOX Used in Theperioperative Treatment","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Xiangdong Cheng","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT05715931","title":"Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Yu jiren","has_results":false},{"nct_id":"NCT03092518","title":"Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05275062","title":"Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":6,"lead_sponsor_name":"Beijing Immunochina Medical Science & Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04752358","title":"ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Adaptimmune","has_results":true},{"nct_id":"NCT04510285","title":"A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}